Financhill
Buy
59

GMED Quote, Financials, Valuation and Earnings

Last price:
$71.90
Seasonality move :
6.7%
Day range:
$70.97 - $72.14
52-week range:
$50.00 - $94.93
Dividend yield:
0%
P/E ratio:
94.81x
P/S ratio:
3.88x
P/B ratio:
2.34x
Volume:
707.4K
Avg. volume:
1.2M
1-year change:
41.01%
Market cap:
$9.8B
Revenue:
$2.5B
EPS (TTM):
$0.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GMED
Globus Medical
$625.9M $0.74 6.09% 580.52% $97.46
ATEC
Alphatec Holdings
$168.2M -$0.12 21.01% -64.5% $18.04
BSX
Boston Scientific
$4.6B $0.67 18.76% 229.31% $116.12
ITGR
Integer Holdings
$428.7M $1.24 6.46% 76.23% $147.88
MASI
Masimo
$367.8M $1.21 -25.37% 192.38% $195.70
RMD
ResMed
$1.3B $2.36 8.17% 24.05% $263.49
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GMED
Globus Medical
$71.11 $97.46 $9.8B 94.81x $0.00 0% 3.88x
ATEC
Alphatec Holdings
$11.06 $18.04 $1.6B -- $0.00 0% 2.59x
BSX
Boston Scientific
$103.19 $116.12 $152.6B 75.32x $0.00 0% 8.75x
ITGR
Integer Holdings
$125.59 $147.88 $4.4B 59.52x $0.00 0% 2.53x
MASI
Masimo
$163.65 $195.70 $8.8B 116.80x $0.00 0% 4.23x
RMD
ResMed
$236.49 $263.49 $34.7B 26.54x $0.53 0.88% 6.94x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GMED
Globus Medical
9.6% 2.870 3.9% 1.72x
ATEC
Alphatec Holdings
102.52% 1.134 43.55% 1.45x
BSX
Boston Scientific
32.79% 1.029 -- 0.46x
ITGR
Integer Holdings
43.46% 1.567 30% 1.99x
MASI
Masimo
42.11% 1.411 8.64% 1.08x
RMD
ResMed
10.82% 0.505 2.05% 1.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GMED
Globus Medical
$393.9M $77.1M 2.31% 2.56% 11.72% $193.2M
ATEC
Alphatec Holdings
$121.6M -$20.9M -29.29% -691.37% -14.56% $6.8M
BSX
Boston Scientific
$3.2B $937M 6.43% 8.96% 19.02% $1.2B
ITGR
Integer Holdings
$120.3M $55.8M 2.85% 4.85% -0.02% $6.1M
MASI
Masimo
$244.7M -$54.6M -14.23% -23.05% -58.55% $47.5M
RMD
ResMed
$766.4M $426.3M 22.47% 25.76% 33% $554.9M

Globus Medical vs. Competitors

  • Which has Higher Returns GMED or ATEC?

    Alphatec Holdings has a net margin of 4.03% compared to Globus Medical's net margin of -18.85%. Globus Medical's return on equity of 2.56% beat Alphatec Holdings's return on equity of -691.37%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
    ATEC
    Alphatec Holdings
    68.77% -$0.23 $562M
  • What do Analysts Say About GMED or ATEC?

    Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 37.06%. On the other hand Alphatec Holdings has an analysts' consensus of $18.04 which suggests that it could grow by 63.13%. Given that Alphatec Holdings has higher upside potential than Globus Medical, analysts believe Alphatec Holdings is more attractive than Globus Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    6 4 0
    ATEC
    Alphatec Holdings
    6 1 0
  • Is GMED or ATEC More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.249%.

  • Which is a Better Dividend Stock GMED or ATEC?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or ATEC?

    Globus Medical quarterly revenues are $657.3M, which are larger than Alphatec Holdings quarterly revenues of $176.8M. Globus Medical's net income of $26.5M is higher than Alphatec Holdings's net income of -$33.3M. Notably, Globus Medical's price-to-earnings ratio is 94.81x while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.88x versus 2.59x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.88x 94.81x $657.3M $26.5M
    ATEC
    Alphatec Holdings
    2.59x -- $176.8M -$33.3M
  • Which has Higher Returns GMED or BSX?

    Boston Scientific has a net margin of 4.03% compared to Globus Medical's net margin of 14.45%. Globus Medical's return on equity of 2.56% beat Boston Scientific's return on equity of 8.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
    BSX
    Boston Scientific
    68.84% $0.45 $32.6B
  • What do Analysts Say About GMED or BSX?

    Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 37.06%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.53%. Given that Globus Medical has higher upside potential than Boston Scientific, analysts believe Globus Medical is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    6 4 0
    BSX
    Boston Scientific
    23 4 0
  • Is GMED or BSX More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

  • Which is a Better Dividend Stock GMED or BSX?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or BSX?

    Globus Medical quarterly revenues are $657.3M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Globus Medical's net income of $26.5M is lower than Boston Scientific's net income of $674M. Notably, Globus Medical's price-to-earnings ratio is 94.81x while Boston Scientific's PE ratio is 75.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.88x versus 8.75x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.88x 94.81x $657.3M $26.5M
    BSX
    Boston Scientific
    8.75x 75.32x $4.7B $674M
  • Which has Higher Returns GMED or ITGR?

    Integer Holdings has a net margin of 4.03% compared to Globus Medical's net margin of -5.14%. Globus Medical's return on equity of 2.56% beat Integer Holdings's return on equity of 4.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
    ITGR
    Integer Holdings
    27.51% -$0.66 $2.8B
  • What do Analysts Say About GMED or ITGR?

    Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 37.06%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 17.74%. Given that Globus Medical has higher upside potential than Integer Holdings, analysts believe Globus Medical is more attractive than Integer Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    6 4 0
    ITGR
    Integer Holdings
    6 2 0
  • Is GMED or ITGR More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

  • Which is a Better Dividend Stock GMED or ITGR?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or ITGR?

    Globus Medical quarterly revenues are $657.3M, which are larger than Integer Holdings quarterly revenues of $437.4M. Globus Medical's net income of $26.5M is higher than Integer Holdings's net income of -$22.5M. Notably, Globus Medical's price-to-earnings ratio is 94.81x while Integer Holdings's PE ratio is 59.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.88x versus 2.53x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.88x 94.81x $657.3M $26.5M
    ITGR
    Integer Holdings
    2.53x 59.52x $437.4M -$22.5M
  • Which has Higher Returns GMED or MASI?

    Masimo has a net margin of 4.03% compared to Globus Medical's net margin of -58.2%. Globus Medical's return on equity of 2.56% beat Masimo's return on equity of -23.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
    MASI
    Masimo
    40.74% -$6.52 $1.8B
  • What do Analysts Say About GMED or MASI?

    Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 37.06%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 19.58%. Given that Globus Medical has higher upside potential than Masimo, analysts believe Globus Medical is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    6 4 0
    MASI
    Masimo
    4 3 0
  • Is GMED or MASI More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

  • Which is a Better Dividend Stock GMED or MASI?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMED or MASI?

    Globus Medical quarterly revenues are $657.3M, which are larger than Masimo quarterly revenues of $600.7M. Globus Medical's net income of $26.5M is higher than Masimo's net income of -$349.6M. Notably, Globus Medical's price-to-earnings ratio is 94.81x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.88x versus 4.23x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.88x 94.81x $657.3M $26.5M
    MASI
    Masimo
    4.23x 116.80x $600.7M -$349.6M
  • Which has Higher Returns GMED or RMD?

    ResMed has a net margin of 4.03% compared to Globus Medical's net margin of 28.26%. Globus Medical's return on equity of 2.56% beat ResMed's return on equity of 25.76%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
    RMD
    ResMed
    59.33% $2.48 $6.2B
  • What do Analysts Say About GMED or RMD?

    Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 37.06%. On the other hand ResMed has an analysts' consensus of $263.49 which suggests that it could grow by 11.42%. Given that Globus Medical has higher upside potential than ResMed, analysts believe Globus Medical is more attractive than ResMed.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMED
    Globus Medical
    6 4 0
    RMD
    ResMed
    8 6 1
  • Is GMED or RMD More Risky?

    Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

  • Which is a Better Dividend Stock GMED or RMD?

    Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.88% to investors and pays a quarterly dividend of $0.53 per share. Globus Medical pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GMED or RMD?

    Globus Medical quarterly revenues are $657.3M, which are smaller than ResMed quarterly revenues of $1.3B. Globus Medical's net income of $26.5M is lower than ResMed's net income of $365M. Notably, Globus Medical's price-to-earnings ratio is 94.81x while ResMed's PE ratio is 26.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.88x versus 6.94x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMED
    Globus Medical
    3.88x 94.81x $657.3M $26.5M
    RMD
    ResMed
    6.94x 26.54x $1.3B $365M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is down 22.08% over the past day.

Buy
65
MYRG alert for May 2

MYR Group [MYRG] is up 5.11% over the past day.

Sell
35
FTAI alert for May 2

FTAI Aviation [FTAI] is up 3.53% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock